SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is trending after its Q2 earnings significantly beat revenue and EPS estimates, coupled with an increased FY26 revenue forecast, fueling investor optimism for its role in AI infrastructure. Despite strong top-line growth and community calls of undervaluation, ongoing concerns about gross margin compression and alleged market manipulation remain key discussion points.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending following a significant plunge after an earnings miss and weak guidance, compounded by a CEO shake-up. The community is sharply divided, with some calling it an obsolete "dinosaur" while others view its low valuation and strong cash flow as a compelling buying opportunity.

Figma, Inc. is an AI-powered design platform that enables seamless collaboration across the entire product development lifecycle. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma ($FIG) is trending amid a sharp price decline to new lows, with community discussions largely centered on significant insider selling and the impending impact of lock-up expirations. While bulls view the current valuation as a compelling buying opportunity for a leading design platform integrating AI, bears are concerned about fundamental challenges and the stock potentially being rendered obsolete by broader AI advancements.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending after an unexpected pre-release of cautious 2026 guidance, projecting a sales and profit decline, triggered a sharp market sell-off. The community is deeply divided between those panicking over intensifying competition and pricing pressures in the GLP-1 market, and those viewing it as a significant "buy the dip" opportunity.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending amid a persistent sell-off driven by broader software sector weakness and sustained CEO share sales, even as bulls fiercely accumulate, convinced of its deeply undervalued position as a leader in Agentic AI and enterprise automation with robust fundamentals.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Unity Software is experiencing a sharp sell-off amid investor concern that Google's Project Genie AI for generating virtual worlds threatens its business. However, a significant portion of the community views this as an irrational overreaction and a prime buying opportunity, arguing that AI tools will ultimately enhance Unity's role in game development.

OpenAI pioneers large-language models like GPT and DALL·E, enabling advanced AI applications. Their research emphasizes both cutting-edge capability and responsible deployment strategies.

OpenAI PreStocks

OpenAI is a major talking point as investors actively debate its disruptive potential versus its financial viability, with significant discussion around its massive funding needs, competitive pressures from rivals like Google, and its substantial impact on partners like Microsoft and Nvidia.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending following its earnings report, which, despite beating both EPS and revenue estimates, saw its stock decline after reporting due to perceived conservative Q1 guidance. The community is debating whether this reaction is market manipulation or reflective of concerns about valuation and the stock's historical post-earnings volatility.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending amidst reports of US security reviews stalling its H200 AI chip sales to China, leading to paused orders, while community discussion focuses on CEO Jensen Huang's denials of "drama" surrounding the company's significant investment plans with OpenAI.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending due to sharp market reactions to its substantial AI investments, especially with OpenAI, driving a notable decline in its stock price and impacting the broader software sector. Community sentiment is polarized, with many buyers seizing the perceived discount and strong fundamentals, while others anticipate further downside given concerns over AI spending ROI and technical chart patterns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The committee had issued a negative opinion on approving the new dosing regimen in October after it deemed the submitted data as insufficient to conclude on efficacy.</li><li>Protalix said that it will be eligible to receive a regulatory milestone payment of $25 million from Chiesi Global Rare Diseases if the new dosing regimen is approved by the EMA.</li></ul>Shares of Protalix BioTherapeutics, Inc. (PLX) closed 13% higher on Friday after it announced that a European Medicines Agency committee has recommended approval of a new dosing regimen for pegunigalsidase alfa, marketed as Elfabrio, in Fabry disease.The Committee for Medicinal Products for Human Use <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.protalix.com/news-releases/news-release-details/chiesi-global-rare-diseases-and-protalix-biotherapeutics-4">recommended</a> approval of the 2mg/kg every-4-weeks dosing regimen in Fabry disease adult patients. Currently approved dosing regimen requires patients to visit infusion centers every two weeks for treatment while the proposed new regimen would allow it to be stretched to every four weeks.<h2 class="st-heading-2">Turnaround</h2>The positive opinion follows CHMP’s re-examination of the company’s application for the additional dosing regimen. The committee had issued a negative opinion on approving the new dosing regimen in October after it deemed the submitted data as insufficient to conclude on efficacy.Protalix said that it will be eligible to receive a regulatory milestone payment of $25 million from Chiesi Global Rare Diseases if the new dosing regimen is approved by the EMA. The agency is expected to announce a decision by March 2026.Fabry disease is a rare, inherited X-linked lysosomal storage disorder caused by a deficiency in the alpha-galactosidase A enzyme, leading to harmful accumulation of fats in cells. Symptoms include severe neuropathic pain in hands/feet, skin lesions, decreased sweating, and organ damage.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around PLX stock improved from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.A Stocktwits user appreciated that the company was persistent in getting a positive opinion. However, the stock should have rallied more on the news, they said.“But the $25 million is great news and hopefully should lessen the risk of capital raise for their gout trials. Finally, one decent obstacle out of the way,” they wrote.<stembedurl>https://www.stocktwits.com/BryGuy29/message/643515194</stembedurl><a href="https://stocktwits.com/symbol/PLX">PLX stock</a> has dropped about 2% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/peloton-reportedly-lays-off-11-percent-workforce/cmySvT7R4Sv">Peloton Reportedly Lays Off 11% Workforce Including Engineers In Cost-Cutting Efforts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

PLX Shares Jump 13% On EMA Committee’s Turnaround On New Dosing Regimen For Fabry Disease Therapy

The Committee for Medicinal Products for Human Use recommended approval of the 2mg/kg every-4-weeks dosing regimen in Fabry disease adult patients.

Equity

The Committee for Medicinal Products for Human Use recommended approval of the 2mg/kg every-4-weeks dosing regimen in Fabry disease adult patients.


PLX Investors Have Opportunity to Join Protalix BioTherapeutics, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Protalix BioTherapeutics, Inc. (Protalix or the Company) (NYSE...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

Protalix BioTherapeutics (PLX) and Chiesi Global Rare Diseases announced on Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a negative opinion on the request to approve a new dosing regimen for Elfabrio.The company was seeking approval of a dosing regimen of 2 mg/kg body weight infused every four weeks for Elfabrio. The currently approved dosing regimen in the European Union is 1 mg/kg body weight infused every two weeks for the treatment of adults with confirmed Fabry disease, a rare genetic disorder leading to the buildup of a fatty substance called globotriaosylceramide in cells throughout the body.Fabry disease can cause a range of serious signs and symptoms, including fatigue, chronic pain, gastrointestinal issues, decreased ability to sweat, progressive kidney failure, heart complications, and increased risk of stroke. It affects both males and females and is caused by a deficiency of the enzyme alpha-galactosidase A.However, Protalix CEO <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/17/3168523/0/en/Chiesi-Global-Rare-Diseases-and-Protalix-Biotherapeutics-Acknowledge-CHMP-Negative-Opinion-on-Every-Four-Week-Dosing-Regimen-of-Elfabrio-pegunigalsidase-alfa-in-the-EU.html">said</a> that the results of the review do not change the priority of the company to reduce treatment burden for patients with Fabry disease. The two companies also clarified that they intend to keep working together.Shares of PLX dropped 28% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/PLX">PLX stock</a> rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours while message volume stayed at ‘high’ levels.Protalix submitted the data to the committee for review, which included two new studies and analyses from prior studies. However, the data was not deemed sufficient to conclude on efficacy, the company saidPLX stock is up by 28% this year and by 120% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/boston-scientific-to-acquire-privately-held-pain-solutions-developer-nalu-medical-for-about-533-million/ch6se8ER38d">Boston Scientific To Acquire Privately-Held Pain Solutions Developer Nalu Medical For About $533M</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

Protalix BioTherapeutics Stock Tumbled 28% Today: Why The Latest CHMP Opinion Is Sparking Concerns Among Investors?

However, Protalix CEO said that the results of the review do not change the priority of the company to reduce treatment burden for patients with Fabry disease.

Wall Street analysts downgraded Regulus Therapeutics on Wednesday following its acquisition by Swiss drugmaker Novartis, citing limited room for upside after the deal valued Regulus at up to $1.7 billion.JonesResearch cut its rating to ‘Hold’ from ‘Buy’ and lowered its price target to $7 from $8, calling the offer “highly favorable” in light of Regulus’ upcoming Phase 3 trial financing needs, according to The Fly.Canaccord Genuity also&nbsp;reportedly downgraded the stock to ‘Hold,’ slashing its target to $11 from $28.&nbsp;Meanwhile,&nbsp;Wells Fargo reportedly cut its rating on Regulus to ‘Equal Weight’ from ‘Overweight,’ raising its target to $9 from $6 to reflect the contingent value right (CVR) component. Leerink Partners and Oppenheimer issued similar downgrades.Under the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/regulus-therapeutics-stock-rockets-on-novartis-buy-offer/chXTfRKRbiP">agreement</a>, Regulus shareholders will receive $7 per share in cash and an additional $7 via a CVR, contingent on U.S. regulatory approval of its lead candidate, farabursen.&nbsp;The upfront payment represents a 108% premium to Regulus’ April 29 closing price and a 274% premium to its 60-day volume-weighted average.&nbsp;The transaction, unanimously approved by both companies’ boards, is expected to close in the second half of 2025, pending regulatory approvals and majority shareholder tender.Shares of Regulus surged to their highest levels since 2021 following the news and are up 6.4% year-to-date, while Novartis has gained 4.8%, both outperforming broader markets.The Dow is down 4.1%, the S&amp;P 500 has lost 5.1%, and the Nasdaq is off 1.6% over the same period.On Stocktwits, 24-hour message volume for Regulus jumped by 2,863% amid “extremely bullish” sentiment.One user congratulated Regulus shareholders, particularly recent buyers, and suggested that the growing interest in rare diseases could make companies like Protalix BioTherapeutics, Zevra Therapeutics, and Esperion Therapeutics potential targets going forward.<stembedurl>https://stocktwits.com/OldManLogan/message/613115970</stembedurl>Another Stocktwits user speculated that Regulus shares could double from current levels, fueled by FDA-related optimism and the potential for a competing bid to top Novartis' offer.<stembedurl>https://stocktwits.com/ST_Tropez_Trading/message/613203730</stembedurl>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Regulus Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead

Regulus Therapeutics shares surged after Novartis announced a $1.7 billion acquisition, but analysts downgraded the stock citing limited upside. Retail sentiment remained bullish, with speculation of a higher bid or FDA-driven gains.

Pluxee shares jump 11% on strong Q1 operating revenue growth

Investing.com -- Pluxee NV (EPA:PLX) reported 12.1% organic growth in first-quarter operating revenue, beating market expectations, and sending its shares soaring 11% in European trading Wednesday.

Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include Alidornase alfa, PRX-115 and PRX-11. The company was by Yoseph Shaaltiel in 1993 and is headquartered in Hackensack, NJ.

Protalix BioTherapeutics Inc.

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $GOOGL earnings on Wednesday?

PLX
Protalix BioTherapeutics Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest PLX News

PLXProtalix BioTherapeutics Inc.